Artiva Biotherapeutics (ARTV) Capital Expenditures (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Capital Expenditures of $242000.0 for Q1 2026, down 72.56% year-over-year from $882000.0 in Q1 2025, and up 202.98% quarter-over-quarter from -$235000.0 in Q4 2025.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) Capital Expenditures (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Capital Expenditures for 4 consecutive years, with $242000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 72.56% year-over-year to $242000.0; the TTM figure through Mar 2026 stood at -$449000.0 (down 148.49% YoY), while the FY2025 annual figure was $191000.0, up 235.09% from the prior year.
- Capital Expenditures climbed to $242000.0 in Q1 2026 per ARTV's latest filing, from -$235000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.7 million in Q3 2023 and bottomed at -$2.8 million in Q4 2023.
- Historically, Capital Expenditures has averaged $37636.4 across 4 years, with a median of $143000.0 in 2025.
- On a YoY basis, Capital Expenditures climbed as much as 6684.62% in 2025 and fell as far as 255.63% in 2025.
- Artiva Biotherapeutics' Capital Expenditures stood at -$2.8 million in 2023, then surged by 105.47% to $151000.0 in 2024, then sank by 255.63% to -$235000.0 in 2025, then surged by 202.98% to $242000.0 in 2026.
- Business Quant data shows ARTV's Capital Expenditures at $242000.0 in Q1 2026, -$235000.0 in Q4 2025, and $143000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Artiva Biotherapeutics | 441.23 Mn | 441.23 Mn | - | 359,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 359,000.00 |
| Mar 31, 2026 | 298,000.00 |
| Dec 31, 2025 | 421,000.00 |
| Sep 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 684,000.00 |
| Mar 31, 2025 | 882,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Sep 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 513,000.00 |
| Mar 31, 2024 | -31,000.00 |
| Dec 31, 2023 | 636,000.00 |
| Sep 30, 2023 | 179,000.00 |